Blocking JAM-C in vivo impairs MM progression and dissemination in tumor-bearing mice. (A) Three representative mice from experimental groups that were treated with either an isotype control (n = 8) or αJAM-C antibody (n = 9) from ventral (left panel) and dorsal (right panel) views over time after treatment. (B) Absolute signal quantification by whole body BLI from ventral views over time after treatment (P = .009; 2-way analysis of variance [ANOVA]). The horizontal lines represent the mean of photons. (C) Number of additional tumor foci within the isotype control (ctrl) and αJAM-C–treated group over time after treatment (P = .031; Wilcoxon test). (D) BLI images of 4 representative bone pairs of isotype-treated (dots) and αJAM-C–treated (squares) mice at day 21 and (F) corresponding graphical and statistical signal quantification (P = .026; 2-way ANOVA). (E) Survival rate of isotype-treated and αJAM-C–treated mice over time after treatment (P = .019; Gehan-Breslow-Wilcoxon test). (G) Frequency of GFP⁺ cells from BM of isotype- or αJAM-C–treated mice determined by FACS analysis (P = .028; Mann-Whitney U test). Error bars indicate SD. The horizontal lines represent the % of GFP positive cells.